Latest clinical research focus on the Targeted Therapy

State-of-the-art in EGFR mutant NSCLC

As more and more targeted therapies are developed for EGFR mutant NSCLC, clinical evidence on their roles in treatment has mounted. In this DIALOG webinar, Professor Barbara Melosky (Canada) shares the latest updates in EGFR mutant NSCLC treatment, from first-line and second-line data, to uncommon mutations.

Estimated Time of Completion: 5 mins.

The latest in Osimertinib-Resistant NSCLC treatment

Osimertinib has become established in the treatment of EGFR TKI-resistant NSCLC but with its use followed the emergence of osimertinib-resistant clones. In this DIALOG webinar, Professor Barbara Melosky (Canada) runs through the emerging strategies in combating osimertinib resistance.

Estimated Time of Completion: 5 mins.

About the speaker

Professor Barbara Melosky, MD, FRCP(C), is a clinical professor of medicine at the University of British Columbia and a Medical Oncologist at the BC Cancer Center in Vancouver. She graduated from medical school at the University of Manitoba and completed a residency in Internal Medicine and a Fellowship in Oncology at the University of British Columbia. Dr. Melosky specializes in thoracic malignancies.